Genmab Says Petosemtamab-Keytruda Combo Cut Mortality Risk 50%

John Kim

1 min read

Add as a preferred source on Google

Genmab Says Petosemtamab-Keytruda Combo Cut Mortality Risk 50%

The Phase 3 data involved certain patients with head and neck cancer. Petosemtamab is a bispecific antibody therapy.

By John Kim

Published Oct 28, 2026, 3:23 PM EDT

Unmarked medicine vials sit beside a clear infusion line / TokenPost.ai (macro)

Genmab A/S said Oct. 28 that petosemtamab combined with Merck’s Keytruda (pembrolizumab) cut mortality risk by 50% in Phase 3 data involving certain patients with head and neck cancer.

Petosemtamab is a bispecific antibody therapy.

John Kim

John Kim reports on the digital-asset business for TokenPost. Send corrections or tips to info@tokenpost.com.